Rhythm Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RYTM) $33.63 +0.20 (+0.60%) (As of 03:27 PM ET) Add Compare Share Share Today's Range$32.96▼$34.0450-Day Range$21.39▼$34.6452-Week Range$15.50▼$35.29Volume189,566 shsAverage Volume665,134 shsMarket Capitalization$1.99 billionP/E RatioN/ADividend YieldN/APrice Target$37.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside11.5% Upside$37.71 Price TargetShort InterestBearish15.92% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.36Based on 5 Articles This WeekInsider TradingSelling Shares$724,583 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.21) to ($2.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector806th out of 949 stocksPharmaceutical Preparations Industry393rd out of 447 stocks 2.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.71, Rhythm Pharmaceuticals has a forecasted upside of 11.5% from its current price of $33.83.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.92% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 19.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 1.9 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Rhythm Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $724,583.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.21) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 10.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comHunter C. Smith Sells 10,974 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockNovember 26, 2023 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High at $35.29December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 22, 2023 | msn.comFormer ‘Rhythm City’ Actress Mapula Mafole Mourns the Loss of Her Father: “I’m Still Not Okay”November 22, 2023 | msn.comThe Brickyard, Carlisle to host Rhythm of the 90s in May 2024November 21, 2023 | seekingalpha.comRhythm Pharmaceuticals: Major Catalysts Due For Weight Loss SpecialistNovember 17, 2023 | finance.yahoo.comInsider Sell Alert: Joseph Shulman of Rhythm Pharmaceuticals Inc Cashes Out SharesNovember 16, 2023 | seekingalpha.comRYTM Rhythm Pharmaceuticals, Inc.December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 13, 2023 | markets.businessinsider.comBuy Rating for Rhythm Pharmaceuticals: Imcivree’s Promise for Hypothalamic Obesity Treatment Outweighs Competing ThreatsNovember 13, 2023 | chron.comOut and About: Midland Shared Spaces Rhythm & BoozeNovember 13, 2023 | finance.yahoo.comInvestors ignore increasing losses at Rhythm Pharmaceuticals (NASDAQ:RYTM) as stock jumps 5.1% this past weekNovember 9, 2023 | markets.businessinsider.comPositive Outlook for Rhythm Pharmaceuticals: FDA Approval, Impressive Clinical Trials, and Financial Stability Justify Analyst’s Buy RatingNovember 9, 2023 | markets.businessinsider.comRhythm Pharmaceuticals: Financial Stability and Growth Prospects Justify Buy RatingNovember 7, 2023 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue EstimatesNovember 7, 2023 | seekingalpha.comRhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 7, 2023 | finance.yahoo.comRhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business UpdateNovember 7, 2023 | finance.yahoo.comRhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business UpdateNovember 7, 2023 | finance.yahoo.comRhythm Pharmaceuticals Inc (RYTM) Reports Q3 2023 Financial ResultsNovember 6, 2023 | msn.comRhythm Pharmaceuticals Q3 2023 Earnings PreviewNovember 2, 2023 | finance.yahoo.comRhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)November 2, 2023 | msn.comRhythm Pharmaceuticals (RYTM) Price Target Increased by 6.69% to 41.59November 1, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 30, 2023 | markets.businessinsider.comSetmelanotide’s Promising Results and Expanding Market Potential Drive Analyst’s Buy Rating on Rhythm PharmaceuticalsOctober 29, 2023 | msn.comTickets for Jools Holland and his Rhythm and Blues Orchestra in Leicester available on TicketmasterOctober 25, 2023 | businesswire.comResults Are In: AI-Powered Salesloft Rhythm Drives Meaningful Productivity and Revenue Outcomes for Global Sales OrganizationsOctober 25, 2023 | finance.yahoo.comRhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023See More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees177Year FoundedN/APrice Target and Rating Average Stock Price Target$37.71 High Stock Price Target$56.00 Low Stock Price Target$27.00 Potential Upside/Downside+12.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,120,000.00 Net Margins-299.33% Pretax Margin-298.74% Return on Equity-85.92% Return on Assets-53.30% Debt Debt-to-Equity RatioN/A Current Ratio6.57 Quick Ratio6.41 Sales & Book Value Annual Sales$23.64 million Price / Sales83.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book10.01Miscellaneous Outstanding Shares59,100,000Free Float56,318,000Market Cap$1.98 billion OptionableOptionable Beta1.66 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 69)Chairman, President & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 54)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 50)Executive VP & Head of International Comp: $747.43kMs. Jennifer L. Chien (Age 48)Executive VP & Head of North America Comp: $644.2kMr. Christopher German (Age 52)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief Human Resources Officer More ExecutivesKey CompetitorsTG TherapeuticsNASDAQ:TGTXIDEAYA BiosciencesNASDAQ:IDYARocket PharmaceuticalsNASDAQ:RCKTCymaBay TherapeuticsNASDAQ:CBAYProthenaNASDAQ:PRTAView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 2,778 shares on 12/1/2023Ownership: 0.233%Hunter C SmithSold 10,974 sharesTotal: $384,309.48 ($35.02/share)Deutsche Bank AGBought 3,227 shares on 11/24/2023Ownership: 0.046%Polar Capital Holdings PlcBought 250,000 shares on 11/22/2023Ownership: 4.230%Comerica BankBought 45,671 shares on 11/21/2023Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price objectives for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $56.00. On average, they anticipate the company's share price to reach $37.71 in the next year. This suggests a possible upside of 11.5% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2023? Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has increased by 16.2% and is now trading at $33.83. View the best growth stocks for 2023 here. Are investors shorting Rhythm Pharmaceuticals? Rhythm Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,410,000 shares, a drop of 19.2% from the October 31st total of 11,650,000 shares. Based on an average daily volume of 571,000 shares, the days-to-cover ratio is currently 16.5 days. View Rhythm Pharmaceuticals' Short Interest. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). The company earned $22.50 million during the quarter, compared to analysts' expectations of $22.18 million. Rhythm Pharmaceuticals had a negative net margin of 299.33% and a negative trailing twelve-month return on equity of 85.92%. Rhythm Pharmaceuticals's revenue was up 425.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.79) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (13.99%), Polar Capital Holdings Plc (4.23%), Federated Hermes Inc. (3.96%), FMR LLC (1.47%), Northern Trust Corp (0.85%) and Assenagon Asset Management S.A. (0.72%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.